Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium diffi cile infection (R-CDI) that cannot be cured with antibiotics alone. In addition, FMT is being investigated for a variety of indications where restoration or restructuring of the gut microbial community is hypothesized to be benefi cial. We sought to develop a stable, freeze-dried encapsulated preparation of standardized fecal microbiota that can be used for FMT with ease and convenience in clinical practice and research.
INTRODUCTION
Widespread use of antimicrobial drugs over many decades in medi cine and agriculture has resulted in the emergence of increasing numbers of antibiotic-resistant pathogens, which constitute one of the most urgent growing threats in modern healthcare ( 1, 2 ) . In addition, antibiotics increase vulnerability to infections by lowering colonization resistance that is normally provided by the host's own microbiota ( 3 ) . Th erefore, there is a need for more targeted treatments against pathogens that can spare the host microbiota, and/or restorative treatments that can recover the normal composition of gut microbiota.
Th e syndrome of recurrent Clostridium diffi cile infection (R-CDI) is a common clinical challenge that captures the essential pitfalls of reliance on broad-spectrum antibiotics for treatment ( 4 ) .
Successful Resolution of Recurrent Clostridium diffi cile
Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study Th e standard antibiotics for this infection, e.g., metronidazole and vancomycin, suppress gut microbiota leading to a disruption of normal microbial community structure, dysbiosis, and a decrease in overall microbial diversity. CDI reoccurs aft er cessation of antibiotic therapy, when the loss of protective microbiota allows C. diffi cile spore germination, expansion of vegetative forms of C. diffi cile bacteria and production of endotoxins. Restoration of the gut microbial community structure and function via fecal microbiota transplantation (FMT)-transplantation of the gut microbial community from healthy donor stool-has emerged as a highly eff ective treatment of refractory R-CDI ( 5, 6 ) .
FMT has developed rapidly over the last several years from a crude procedure involving diff erent routes of administration of raw stool from patient-identifi ed donors to the use of purifi ed and cryopreserved standardized preparations of fecal microbiota from highly selected donors ( 7 ) . Although colonoscopic administration of FMT has the advantage of a direct application providing potentially clinical relevant diagnostic information ( 8 ) , an oral preparation is preferable for many patients due to its greater ease of administration ( 9 ) . Encapsulated, frozen microbiota can be delivered orally and results in successful treatment of R-CDI ( 10 ); however, the practicality of this preparation is somewhat limited by uniformity, storage, and shelf-life issues. In addition, little is known about microbiome changes that follow capsule FMT.
We sought to develop the next-generation form of encapsulated FMT using a freeze-dried preparation of microbiota that could tolerate a range of temperatures to allow ease of handling and satisfy the following conditions: (i) the freeze-drying procedure should preserve viability and diversity of the entire taxonomic spectrum of microbiota, (ii) the resulting material should have physicochemical properties that enable standardized encapsulation, (iii) the encapsulation procedure should not compromise the viability of microbiota, and (iv) the microbiota should engraft into the colon and successfully treat R-CDI. Here we describe development of such a preparation and the results of its use in clinical practice.
METHODS

Freeze-dried fecal microbiota
Fecal bacteria were prepared using the standard methods as previously described ( 7 ), except that glycerol was substituted with one of the following cryoprotectants (all chemicals were USP grade or better and prepared in PBS, pH 7.0): 5% sucrose only; 10% sucrose only; 10% skim milk only; 5% trehalose only; 10% trehalose only; 10% trehalose plus 2.5% sucrose; 5% trehalose plus 2.5% sucrose; 5% mannitol only; or 10% mannitol only. Th e lyophilizer (LyoStar II, Stone Ridge, NY) used a shelf temperature of −20 °C for 36 h followed by 6 h at +30 °C. All steps were done under 100 mT vacuum or less, and the fi nal product was held at +20 °C until used. Th e total dose was 2.5×10 12 cells. Cell numbers were determined by using the Bacteria Counting Kit (Th ermoFisher, Waltham, MA), a Zeiss epifl uorescense microscope equipped with a 470-490 nm excitation fi lter and 500 nm cut-on long pass emission fi lter, and a Petroff Hauser counting chamber. Membrane integrity procedures were also used to directly enumerate microbes present in a diluted sample and to calculate the percentage of microbes with intact membranes present in the intermediate fecal slurry. Th is was done using a BacLight live/dead membrane integrity assay (Th ermoFisher, Waltham, MA) and the microscope and counting chamber described above.
Mice
Germ-free mice were bred and maintained in the germ free facility at the Mayo Clinic (Rochester, MN, USA). Animals were administered microbiota or PBS via oral gavage needle, 100 μ l per dose. Microbiota preparations included frozen/thawed liquid with 10% glycerol, as described previously or rehydrated microbiota freezedried in 5% trehalose. Th e dosage administered to each mouse, of either frozen or freeze-dried material, was 10 10 cells. Fecal pellets were collected before gavage, as well as at 3, 7, 14, and 21 days following gavage.
Preparation of FMT capsules
Double-encapsulated capsules were prepared by using a fi lled size 0 capsule packaged inside a size 00 capsule. Hypromellose capsules were DRcaps from Capsugel (Morristown, NJ). Capsules were manually fi lled using a 24-hole fi ller (Capsule Machine, Capsule Connection, Prescott, AZ) to a fi nal concentration of ~1×10 11 cells/capsule. Th e capsules were stored at −80 °C (a convenient dry storage option) in 50 ml conical tubes until needed. Once removed from the freezer, a 1 g silica gel canister (Dry Pak Industries, Encino, CA) was added to the container.
Patient population
All patients in this cohort, satisfi ed formal inclusion and exclusion criteria, described previously for the University of Minnesota clinical FMT program ( 8 ) . Briefl y, these inclusion criteria were: (i) informed consent; (ii) documentation of at least two spontaneous recurrences of CDI following the initial episode of the infection; (iii) failure of at least one extended antibiotic regimen (≥6 weeks) to prevent spontaneous recurrence of the infection; (iv) documentation of CDI by stool testing within 3 months of FMT. If the patients qualifi ed for FMT, they were always given the option of microbiota delivery via a colonoscopic route of administration during the consent process. Exclusion criteria for all FMT patients included: (i) anticipation of non-CDI antibiotic treatment within 3 months of FMT; (ii) life expectancy of less than 2 years if the patient is able to tolerate suppressive therapy with vancomycin, 125 mg daily, or rifaximin for patients with liver disease and hepatic encephalopathy. In addition, exclusion criteria for FMT with an encapsulated oral preparation of FMT in this study included: (i) dysphagia, (ii) clinical indications for a diagnostic colonoscopy, including anticipated screening or surveillance colonoscopy within 1 year, hematochezia, iron defi ciency anemia, poor symptomatic responsiveness to antibiotic treatment of CDI, past history of unexplained diarrheal symptoms, (iii) any immunosuppressive therapy or presence of known immune defi ciency (e.g., IgA defi ciency), and (iv) known infl ammatory bowel disease, given likely immunosuppression, importance of mucosal examination at the time of FMT, and uncertainty about location of capsule release, e.g., stricture. Patients excluded specifi cally from capsule FMT were off ered colonoscopic FMT as an option if the general FMT inclusion/exclusion criteria were satisfi ed.
Some patients included in this cohort were recipients of previous FMT, administered via colonoscopy. In our program, patients suff ering a spontaneous recurrence of CDI, i.e., recurrence of the infection without a new antibiotic provocation, are off ered another round of FMT. If the patients suff er a recurrence following a new antibiotic provocation, they are off ered one round of anti-CDI antibiotic (preferably fi daxomicin) and FMT is off ered only following a spontaneous recurrence aft er this antibiotic treatment attempt.
FMT protocol
Donor material used in preparation of FMT capsules was obtained from standard donors as previously described (University of Minnesota IRB donor protocol 1303M29782) ( 7 ) . Two male donors provided material for capsule FMT preparations. A research assistant delivered the FMT capsules to patient homes and reinforced instructions for the FMT protocol. Patients were told they could keep the capsules in the refrigerator for 2 days. Th e patients were allowed only water for 2 h before taking the capsules, and only water was allowed for 2 h aft er taking the capsules during which time the patients had to remain upright. Th e protocol evolved in the course of clinical experience as described further in the results section. Variables included: (i) administration of a colon purgative before capsule FMT (discontinued aft er the fi rst four patients; (ii) acid suppressive medications; (iii) the dose of fecal microbiota, which was decreased in the course of the study due to limited quantity of prepared material.
Clinical study design
Th is is a single center (University of Minnesota) pragmatic study describing the entire clinical experience with capsule FMT from June 2014 to March 2016. Failure of FMT was defi ned as spontaneous relapse of diarrheal symptoms, and positive stool testing for C. diffi cile toxin B by PCR, within 2 months of administration. Diarrhea was defi ned as ≥3 loose/watery stools per day for ≥2 consecutive days or a signifi cant change in bowel habits toward diarrhea combined with clinical suspicion for CDI recurrence, e.g., abdominal cramps, fatigue. C. diffi cile toxin B was measured in all patients who noted or complained of loose stools, regardless of frequency. Patients were visited at their home by the study research staff before capsule FMT, at weeks 2 and 4, and longerterm time points at 3 and 6-12 months post-FMT. Patients were able and encouraged to promptly communicate any concerns at all times to the research and clinic staff , as well the principal investigator. All patients were seen in clinic aft er 2 months for a follow-up clinic visit following capsule FMT and were instructed to remain in contact with the clinic indefi nitely with any new questions or concerns and any new prescriptions for antibiotics by other providers. Th e study was approved by the University of Minnesota Institutional Review Board (IRB Protocol 0901M56962). Th e protocol changes in the course of this study and ethics of FMT are further discussed in the Supplementary Material online .
Fecal sample collection
Fecal samples were collected by patients into sterile containers within a week before FMT, on post-FMT days 3, 7, 14, and post-FMT months 1, 3, and 6-12. Th e samples were kept frozen at −20 °C until pick-up by the research staff and transported on ice into the laboratory.
Analysis of fecal microbiota
DNA from single mouse fecal pellets or 250-500 mg of human fecal material was extracted using the PowerSoil DNA Isolation Kit (MoBio Laboratories, Inc., Carlsbad, CA, USA) without deviation from the manufacturer's instructions. Th e microbiome was characterized from patients for whom capsule FMT represented their fi rst intervention (i.e., no prior colonoscopic FMT) and those that experienced any recurrence of infection, regardless of prior intervention. Th e V5+V6 hypervariable regions of the 16S rRNA gene were amplifi ed at the University of Minnesota Genomics Center (UMGC, Minneapolis, MN, USA) using the BSF784/1064R primer set ( 11, 12 ) . Amplicons were gel purifi ed and purifi ed amplicons were pooled in equal amounts for sequencing. Paired-end sequencing was performed by UMGC at a read length of 300 nt using the Illumina MiSeq platform (Illumina, Inc., San Diego, CA, USA). Sequencing data were recovered as fastq fi les and are deposited in the Sequence Read Archive of the National Center for Biotechnology Information under BioProject accession numbers SRP071210 and SRP064361, for germ-free mice and donor/patient samples, respectively.
Sequence processing and analysis, unless otherwise noted, was performed using mothur ver. 1.34.0 (refs. 13,14 ) . Fastq fi les for both forward and reverse reads were trimmed to 150 nt and paired-end joined using fastq-join soft ware ( 15 ) . Sequences were quality trimmed at an average quality score of 35 over a window of 50 nt. Any sequence with homopolymers >8 nt, an ambiguous base, or >2 mismatches from primer sequences was excluded. High-quality sequences were aligned against the SILVA database ver. 119 (ref. 16 ) and subjected to a 2% pre-clustering step ( 17 ) . Chimeras were identifi ed and removed using UCHIME soft ware ( 18 ) . For comparison between samples and data sets, the number of reads per sample was rarefi ed to 50,456 reads for germ-free mice and 11,500 reads for patient comparisons ( 19 ) . Operational taxonomic units were assigned at a 97% identity level using the furthest-neighbor algorithm and taxonomic assignments were made against the RDP14 database ( 20 ) . Engraft ment of the donor microbial community was determined as a percentage of recipient communities that could be attributed to donor samples using the default parameters of the SourceTracker soft ware ( 21 ) .
Statistical analyses
Diff erences in alpha diversity, relative abundances of phyla, and donor similarity were evaluated by ANOVA using XLSTAT version 2015.1.01 (Addinsoft , Belmont, MA, USA). Ordination by principal coordinate analysis, evaluation of the signifi cance COLON/SMALL BOWEL Freeze-Dried Capsule FMT of grouping, and beta diversity statistics were performed using mothur. Analysis of molecular variance was used to determine if grouping was signifi cant ( 22 ) , and analysis of similarity was used to evaluate diff erences in beta diversity ( 23 ) .
RESULTS
Optimization and pre-clinical testing of freeze-dried microbiota
Lyophilization of fecal microbiota preparations is a key step towards generation of a convenient oral dosing form for use in FMT. Th e use of cryoprotectants in lyophilization is required to prevent the formation of cell wall-and membrane-damaging ice crystals during the freezing and desiccation process. Glycerol, which is typically used as a cryoprotectant in preparation of frozen liquid suspensions of microbiota ( 7, 24 ) , is not useful in lyophilization because the viscosity of the resulting end product is not amenable to encapsulation. Certain alternatives, such as milk products or bovine serum, are not suitable for pharmaceutical use due to potential for allergies and issues with batch variation. We tested a number of potential cryoprotectants and found that mannitol and trehalose (at 5% and 10% concentrations) yielded superior preparations that could be ground into a fi ne powder and easily packaged into capsules. However, viability of bacteria with trehalose was superior to that found with mannitol, as measured by a membrane integrity assay which gives the percentage of the total cells with intact membranes ( Supplementary Table 1 online ). In addition, the membrane integrity assay showed the viability of the fresh material was nearly indistinguishable compared to lyophilized fecal microbiota (60% and 56% intact cells, respectively). Consequently, 5% trehalose was chosen as our standard cryoprotectant in the rest of the study.
Since fl exibility in storage and handling conditions is an important issue in clinical care delivery, we tested the stability of freezedried microbiota at diff erent temperatures. Membrane integrity of freeze-dried microbiota remained intact aft er 96 h of storage at room temperature, 4 and −20 °C ( Supplementary Table 2 ). Th e prepared capsules were stored long-term at −80 °C, chosen as the most convenient dry environment available to us ( Supplementary  Table 3 ).
Finally, in order to ensure that the freeze-drying protocol preserved the viability of bacteria in the preparation across the taxonomic spectrum, we measured the engraft ment of the preparations in germ-free mice. Comparison was made to frozen/thawed liquid preparation with glycerol, which had previously been demonstrated to retain full viability following FMT in patients ( 25 ) . Prompt and stable engraft ment of all bacterial phyla was evident for both frozen and freeze-dried treatment groups, as discussed in detail in Supplementary Results , ( Supplementary  Figures 1 and 2 ).
Clinical performance of capsule FMT
Th e basic characteristics of the patients in this clinical cohort were comparable to patients without underlying infl ammatory bowel disease off ered FMT in our program ( Table 1 ) ( 8 ). Th ese patients had an average of 4-5 episodes of CDI since the initial infection and failed all reasonable attempts at breaking the cycle of R-CDI by using antibiotics alone, including an extended course of tapered vancomycin, per inclusion criteria.
Th e clinical capsule FMT protocol evolved over the course of the program experience. Th e dose of microbiota was defi ned by the number of bacteria. Th e initial protocol used ~2.5×10 12 bacteria contained in 24-27 capsules and included a colon purgative before administration to wash out residual antibiotic. However, given the limited number of FMT capsules that were produced during the development phase, we had to decrease the dose in later stages of this experience. Th e fi nal protocol used ~2.1-2.5×10 11 bacteria contained in 2-3 capsules, taken without a preceding purgative as a single dose. Th e protocol changes and the consent process are described in the Supplementary Material . Th e performance of capsule FMT along with diff erent protocol variables are shown in Table 2 . Th e success rate in preventing CDI recurrence over 2 months of follow-up was 87.8% (43/49 patients) in the entire cohort. Th e success rate among all patients for whom the capsule treatment was their fi rst FMT was 89.7% (35/39 patients). One of these patients received broad-spectrum antibiotics during a hospitalization for a complex urinary infection (in the setting of urinary stents) within a day following her capsule FMT and promptly suff ered a recurrence of CDI. Th e success Intercurrent non-CDI antibiotics were antibiotics given for a non-CDI indication during the period following the initial CDI and FMT. However, recurrence of CDI associated with a non-CDI antibiotic was not considered to be a spontaneous CDI recurrence and did not qualify patients for FMT.
changes were not equivalent among diff erent phyla ( Figure 1 ). In particular, the recovery of Bacteroidetes was somewhat delayed relative to what was seen with colonoscopically administered FMT ( 25 ) , and its relative abundance did not stabilize until aft er 1 month following capsule FMT. In order to assess the contribution of donor microbiota engraft ment to the changes in the FMT-associated microbial community structure, we employed SourceTracker soft ware ( see Supplementary Materials ) ( 21 ) . Before FMT this analysis attributed a relatively low fraction (22.6±4.4%) of sequence reads in patient samples to the donors. Donor similarity increased at all time points aft er capsule FMT and was greatest at least 1 month following treatment. Analysis of fecal samples from patients that received high dose capsule FMT (1.25-2.5×10 12 bacteria) vs. low dose (2.1-2. 5×10
11 bacteria) did not show any signifi cant dosedependent diff erences in microbial diversity changes or kinetics of engraft ment, further discussed in Supplementary Results . Similarly, the microbiome analysis did not fi nd any deleterious eff ect of proton pump inhibitors on capsule FMT. Finally, we analyzed the fecal samples from all patients who suff ered a recurrence of CDI following a single treatment with capsule FMT, discussed further in Supplementary Results . Following FMT, the microbiomes of these patients generally became taxonomically more similar to donors, except the one who received antibiotics shortly following the treatment. However, the small number of CDI recurrences precluded elucidation of a clear pattern predictive of FMT failure.
DISCUSSION
Over the last 5 years FMT has rapidly progressed from a rare procedure on the fringes of medicine to a recommended option listed in the mainstream clinical guidelines in management of R-CDI that cannot be managed with standard antibiotics alone ( 31 ) . To a large degree, this rapid adoption of FMT has been enabled by use of pre-made, cryopreserved microbiota. Th e frozen/thawed liquid preparations have been found to be clinically equivalent to freshly prepared microbiota in treatment of R-CDI ( 7, 32, 33 ) and indistinguishable in the kinetics of donor microbiota engraft ment following administration via colonoscopy, enema, or nasogastric tube ( 25 ) . A similar frozen, encapsulated preparation has also been successful when administered orally ( 10, 34, 35 ) . However, the practicality of the frozen, liquid capsules is somewhat limited by issues pertaining to aesthetics, storage, transport, and handling.
Here we described a freeze-dried fecal microbiota preparation that satisfi ed all our preset objectives, including preservation of viability across all bacterial phyla, satisfactory physicochemical characteristics (a fi nely divided powder) that enabled easy encapsulation, and excellent clinical effi cacy. We formally demonstrated that the preparation remains stable for 4 days at a range of temperatures, which is time suffi cient to allow fl exibility in dispensing to patients, and there is every expectation that it will remain stable for much longer periods as long as the environment is dry. We kept the capsules in a −80 °C laboratory freezer merely for convenience rate in breaking the cycle of CDI recurrence for the lowest dosage of microbiota was 93.3% (28/30 patients) and 96.2% (25/26) for patients for whom the capsule treatment was their fi rst FMT. Two patients out of the entire cohort suff ered a spontaneous recurrence (i.e., no new antibiotic provocation) of CDI aft er the 2-month end point. No serious adverse events (death, hospitalization, emergency room or physician visit for a new problem requiring intervention) occurred in this cohort within 2 months following FMT with the exception of the mentioned patient with the urinary infection. Th e patients reported no diffi culty or esthetic concerns taking the capsules at any dose. Approximately a third of patients reported some bowel movement irregularity, bloating, and fl atulence in the initial weeks following capsule FMT.
Changes in the fecal microbiome following FMT
Given the inherent microbiome complexity expected in patients with history of prior FMT, we limited the characterization of the fecal microbiome to samples obtained from patients for whom the capsule treatment was their fi rst FMT. All samples before FMT showed markedly lower microbial diversity compared to the donor microbiota (see Supplementary Table 4 ). Similar to previous investigations of patients undergoing FMT for R-CDI in our own program and others ( 6, (25) (26) (27) (28) (29) (30) , these pre-FMT samples demonstrated markedly increased relative abundance of Proteobacteria (40.7±4.3% vs. 2.0±0.5%, P <0.001) and reductions in the relative abundances of Firmicutes (34.4±3.8% vs. 55.4±3.3%, P =0.443) and Bacteroidetes (8.5±2.7% vs. 39.7±3.4%, P <0.001) compared to the donor samples. Capsule FMT was associated with increased microbial diversity, contraction of the relative abundance of Proteobacteria, and an increase in the relative abundances of Firmicutes and Bacteroidetes, discussed in detail in Supplementary Results . Interestingly, the kinetics of these since it does provide a very dry environment. Additional more long-term storage experiments are ongoing. Th e clinical experience was pragmatic, although we excluded patients with known infl ammatory bowel disease. We made a number of adjustments in the FMT capsule treatment protocol since its original introduction into our clinical program, including elimination of the colon purgative, allowing patients to stay on their proton pump inhibitor, and lowering the dose of microbiota by an order of magnitude. None of these changes have made a detectable impact on the clinical effi cacy or kinetics of fecal microbiota changes following FMT. Th e resulting protocol, which has now become standard in our program, is remarkably simple, necessitating a single In summary, easy-to-handle capsules containing freeze-dried fecal microbiota provide a safe and highly clinically eff ective treatment of refractory R-CDI. Th is form of FMT results in somewhat delayed normalization of recipient fecal microbial community structure compared to colonoscopic FMT. However, this diff erence does not appear to impair clinical response with respect to prevention of CDI recurrence. Clearly, next-generation FMT preparations will continue to be developed, and detailed analysis of microbiota engraft ment and functionality will continue to be useful in guiding this work. Although the patient population was somewhat heterogeneous and the numbers of patients in diff erent subgroups was small, the experience provides a foundation for the design of large, controlled, explanatory clinical trials. Th e FMT preparation described here is certainly easily adaptable to further rigorous study. 
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Th e clinical experience in this study was not constructed as a formal, explanatory clinical trial. Nevertheless, the patients had very close follow-up including systematic home visits by the research assistant for a clinical check-up and collection of fecal samples. All patients were also seen in clinic 2 months aft er capsule FMT and remain in contact with the clinic with any questions or concerns. Th e study design was adequate to capture serious adverse events. As noted, one patient with urinary stents developed a urinary tract infection necessitating hospitalization. It is unlikely that FMT contributed to this problem. Th e rate of minor gastrointestinal symptoms such as irregular bowel movements, bloating, and fl atulence during the initial weeks following capsule administration was comparable to observations made in other post-FMT experiences and formal clinical trials ( 6, 7, 10, 33, 36 ) , and likely represented some element of postinfectious IBS ( 37 ) . Long-term follow-up studies are needed to determine the natural history of post-infectious IBS in this patient population.
Th e capsule FMT resulted in normalization of the fecal microbial community structure. However, it is interesting that the kinetics of microbiome changes was delayed, especially for Bacteroidetes, compared to colonoscopic FMT where full donor microbiota engraft ment is evident within 1 day ( 25 ) . Th is was surprising since recipient germ-free mice did not demonstrate any diff erences among the various bacterial phyla in kinetics of engraft ment. Never theless, the clinical success of capsule FMT suggests that prompt recovery of Bacteroidetes is not required to prevent CDI recurrence.
Th e small failure rate for capsule FMT is comparable to our colono scopic experience. Th e reasons for these failures remain elusive. Th us far we did not identify a pattern of microbiota composition following FMT that would be predictive of FMT failure. Given the high rate of home contamination of R-CDI patients with C. diffi cile spores ( 38 ) , it is possible that patients remain at risk for re-infection during the initial weeks aft er FMT before establishment of the new microbial community and its functionality. We are also currently investigating the possibility that the specifi c C. diffi cile strains from these patients are less responsive to secondary bile-mediated inhibition of germination and growth.
Our study does have some important limitations. Th is was a small, single center, pragmatic study to collect initial clinical experience with capsule FMT, not a trial to determine clinical effi cacy of capsules vs. colonoscopic FMT or another therapeutic preparation. Based on the effi cacy data observed here, a randomized, controlled, double-blind clinical trial to determine eff ectiveness (or non-inferiority) of capsules vs. other forms of FMT would require a very large study. Th e protocol changed over time based on our early experiences and intrinsic constraints. While we noted no diff erence in our cohort between the low dose and high dose capsule FMT, it is possible that larger studies could identify a more subtle diff erence. A simi lar statement applies to concurrent use of proton pump inhibitors.
